Month: September 2020

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2020 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing the Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease has met and reviewed 90-day safety data from the first two patients enrolled in the trial. No significant safety concerns were noted to prevent further dosing, and the next two patients are now cleared for enrollment in the study. The Phase I/II study is a double-blind, randomized clinical trial being conducted in the United States. One patient has been treated with AMT-130, and one patient received the imitation surgery.“We are very pleased with the positive outcome...

LAS VEGAS and VANCOUVER, British Columbia, Sept. 25, 2020 (GLOBE NEWSWIRE) — TAAT LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “Taat”) reports that OTC Markets Group Inc. (“OTCM”), operator of financial markets for 10,000 U.S. and global securities, today announced that the Company has officially “uplisted” from the Pink® market to the OTCQB® exchange (“OTCQB”). In a press release dated July 22, 2020 in which the Company announced it changed its ticker symbol on the Pink® market to TOBAF, the Company also stated it was in the process of applying to uplist to OTCQB. Companies listed on OTCQB must meet high financial standards, and are subject to stringent standards of corporate governance and compliance with securities laws. Taat’s listing on OTCQB provides investors the opportunity...

ALACHUA, Fla., Sept. 25, 2020 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that Karen Zaderej, chairman, CEO, and president, will present at the JMP Securities MedTech Bio Summit. Axogen’s presentation during this virtual summit is scheduled for Thursday, October 1, 2020 at 11:00 a.m. ET.The presentation will be webcast live and can be accessed through the Investors page at www.axogeninc.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.axogeninc.com.About AxogenAxogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral...

PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences:Jefferies 2020 Virtual Gene Therapy/Editing SummitFormat: PresentationDate: Friday, October 2, 2020Time: 11 a.m. ETChardan 4thAnnual Genetic Medicines ConferenceFormat: Fireside ChatDate: Monday, October 5, 2020Time: 1 p.m. ETLive audio webcasts of the presentation and fireside chat will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the webcasts will be available for 30 days following the presentation and fireside chat.About Passage BioPassage Bio is a genetic...

Japan is the first country to approve sofpironium bromide with commercial launch expected later this yearBrickell is on track to initiate its U.S. pivotal Phase 3 program for sofpironium bromide in Q4 2020BOULDER, Colo., Sept. 25, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”), received approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK® in Japan for the treatment of primary axillary (underarm) hyperhidrosis.“We are thrilled with the Japanese approval of sofpironium bromide, which is the first topical prescription...

MALVERN, Pa., Sept. 25, 2020 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA”), a commercial-stage medical technology company focused on designing, developing and marketing a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that additional data from its BRAVO study were presented virtually as posters at the Americas Hernia Society Annual Meeting.The first poster titled, “Surgical site infections and occurrences (SSIs & SSOs) after ventral hernia repair (VHR) with reinforced tissue matrix (RTM), 30-day data from the BRAVO study,” demonstrated that ventral hernia repair using OviTex led to a low incidence of surgical site infections and occurrences. Among patients who experienced an SSO or SSI at 30 days, none required surgical intervention or...

TORONTO, Sept. 25, 2020 (GLOBE NEWSWIRE) — CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), one of the largest integrative healthcare systems in the United States, is pleased to announce that it has upsized and closed its previously announced non-brokered private placement financing (the “Placement”) of units of the Company (the “Units”) led by Merida Capital Partners. The Company issued 34,253,641 Units at an issue price of C$0.15 per Unit (the “Issue Price”) for gross proceeds to the Company of C$5,138,046.15. Each Unit is comprised of one common share of CB2 (a “Share”) and one half of one common share purchase warrant (each whole warrant a “Warrant“). Each Warrant is exercisable to acquire one additional Common Share at an exercise price of $0.20 for a period of twenty-four...

VANCOUVER, British Columbia, Sept. 25, 2020 (GLOBE NEWSWIRE) — First Majestic Silver Corp. (“First Majestic” or the “Company”) announced an update related to the ongoing tax dispute with the Mexican tax authority, the Servicio de Administracion Tributaria (“SAT”) in connection with the 2012 Advance Pricing Agreement (“APA”) granted to Primero Empresa Minera, S.A. de C.V. (“PEM”), a subsidiary of the Company.As previously announced on May 13, 2020, the Company served the Government of Mexico with a Notice of Intent to Submit a Claim (“Notice”) under the provisions of Chapter 11 of North American Free Trade Agreement (“NAFTA”). The service of this Notice initiated a 90-day process for the Government of Mexico to enter into good faith and amicable negotiations with the Company to resolve the dispute. On August...

BEIJING, Sept. 25, 2020 (GLOBE NEWSWIRE) — Pintec Technology Holdings Limited (Nasdaq: PT) (“PINTEC” or the “Company”), a leading independent technology platform enabling financial services in China, today announced that it held its 2020 extraordinary general meeting of shareholders (the “EGM”) on September 25, 2020. At the EGM, the shareholders:resolved as an ordinary resolution that the authorized share capital of the Company be increased and amended to US$250,000, divided into 2,000,000,000 shares of a par value of US$0.000125 each, comprising of (i) 1,750,000,000 Class A ordinary shares of a par value of US$0.000125 each (the “Class A Ordinary Shares”), and (ii) 250,000,000 Class B ordinary shares of a par value of US$0.000125 each (the “Class B Ordinary Shares”), by the creation of 1,401,782,495 authorized but unissued Class...

TORONTO, Sept. 25, 2020 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it has entered into a new white-label supply agreement with DanCann Pharma A/S (“DanCann Pharma”). The company will be serviced by both GMP approved facilities, MediPharm Labs Inc. and MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australia”). This marks MediPharm Labs’ third supply agreement for the export of finished products to Denmark expanding its revenue opportunity in an emerging medicinal cannabis market.DanCann Pharma is a medical cannabis company focused on discovering, developing, manufacturing and commercializing new therapeutic cannabinoids...